Overcoming Difficulties in Oligonucleotide Fragmentation: Utilizing Low-q CID
Oligonucleotide-based therapeutics are transforming biopharmaceutical research, yet their structural complexity continues to test the limits of analytical technology. Precise fragmentation and characterization are critical to ensure accuracy and confidence in sequence analysis, but conventional methods often fall short in handling large or modified molecules.
In this Teach Me in 10, Dr. Amanda Lee, Product Marketing Manager at Thermo Fisher Scientific, explains how optimizing mass spectrometry with low-q collision-induced dissociation (CID) enhances oligonucleotide characterization from digested mRNA to intact 100-mers.
Watch this video to discover:
- How low-q CID overcomes fragmentation challenges
- Streamlined workflows for oligo analysis
- Improved ease-of-use and data reliability
Further resources:
- Orbitrap Ascend BioPharma Tribrid Mass Spectrometer Homepage
- Orbitrap Ascend BioPharma Tribrid Mass Spectrometer Brochure
- BioPharma Finder: A Power Tool for Multiple Biopharmaceutical Workflows. See how one software can help you achieve results from oligonucleotides, intact and top-down protein analyses, peptide mapping and more.
- mRNA Direct Sequence Mapping Using Automated Partial Digestion With Magnetic Nuclease and LC-HRMS. Obtain confident sequence identification of oligonucleotide fragments and comprehensive mapping of mRNA with state-of-the-art software.
Meet the Author
Scientific Content Producer
Interviewing
Product Marketing Manager
